EU backs Glaxo combination drug for cervical cancer

|
GSKLONDON, Dec 1 (Reuters) - GlaxoSmithKline Plc (GSK.L) said on Friday it had won European regulatory approval to sell its Hycamtin medicine as a treatment for cervical cancer in combination with another cancer drug, cisplatin.

The decision was expected after European regulators signalled last month that they intended to approve the new combination treatment.

U.S. regulators approved the combination drug in June.

© Reuters 2006